2022-2023 EVENTS

2022 Events

28 Aug - 01 Sep 2022
The International Surgical Week (ISW)
Kuala Lumpur

31 Aug – 2 Sept 2022
Medical Fair Asia
Marina Bay Sands, Singapore

3-9 September
Medical Fair Asia
Digital, Online

9-10 September 2022
World Pediatrics Conference
Bangkok, Thailand

9-10 September 2022
World Heart and Cardiothoracic Surgery Conference
Bangkok, Thailand

19-21 September 2022
23rd SE-Asian Healthcare & Pharma Show
Kuala Lumpur

27-29 September 2022
Smart Healthcare Expo (Health Malaysia)

27-29 September 2022
Asia Pandemic Congress
Kuala Lumpur Convention Centre

19-20 September 2022
23nd Global Nursing Education Conference
Brisbane, Australia

30 Sep - 2 Oct 2022
Malaysia International Dental Show (MIDS)
Sunway Pyramid Convention Centre, Subang Jaya, Malaysia

7-9 November 2022
Saudi International MedLab Expo
Riyadh International Convention and Exhibition Center

7-9 November 2022
Saudi International Pharma Expo
Riyadh International Convention and Exhibition Center

11-13 November 2022
Eldercare Exhibition and Conference Asia (ELDEX Asia 2022)
Suntex Singapore Exhibition and Convention Centre

14-15 November 2022
Healthcare Asia Pacific
Osaka, Japan

2023 Events

30 May – 1 June 2023
KL Convention Centre, Kuala Lumpur

13-15 September 2023
Medical Fair Thailand
BITEC, Bangkok

Free counters!

Malaysia’s pharmaceutical industry will continue gaining momentum, driven by government incentives to propel local investment in the market, said BMI, a Fitch Solutions company.

It said Malaysia’s New Industrial Master Plan (NIMP) 2030 will promote the integration of value chains for better local production of active pharmaceutical ingredients (API), vaccines and medicines.

“By capitalising on these strategies, we believe Malaysia can attract more investments and position itself as a regional leader in the pharmaceutical industry.

“Pharmaceutical sales were RM11.2 billion in 2022, and we forecast medicine sales to increase to RM15.5 billion in 2027, equating to a compound annual growth rate (CAGR) of 6.7% in local currency terms (5.6% in US dollar terms),” it said in a commentary released today.

NIMP 2030 was launched on Sept 1, with the government announcing an allocation of RM8.2 billion to the national industrial master plan to enhance local manufacturers’ competitiveness.

The country aims to enhance its strategic competitive positioning across 21 industry sectors, with aerospace, chemical, electrical and electronics (E&E), pharmaceutical and medical devices recognised as priority sectors under the NIMP.

Under the plan, the investment, trade and industry ministry, health ministry, Malaysian Investment Development Authority (Mida), and Medical Device Authority (MDA) will collaborate to establish a supportive ecosystem for the industry.

Nevertheless, BMI said that medicine pricing controls would continue to weigh on multinational drugmaker profits and discourage foreign enterprises.

In May 2019, Malaysia announced price control measures for medicines in the country that are based on external reference pricing (ERP), which involves benchmarking local prices against lower drug prices in other markets.

BMI said that the price controls will continue to be implemented at both the wholesale and retail levels.

“As such, it is our view that price controls will have a significant impact on innovative drugmaker profit margins in the country, and this will potentially limit multinational investment,” it noted. – FMT